Regarding systemic efficacy, Cortés et al. recently reported results of second-line treatment of metastatic HER2 + cancer with trastuzumab-deruxtecan, an antibody drug conjugate in comparison with trastuzumab emtansine. This evidence concerns the gene ERBB2 and cancer.